PPARG and Hyperglycemia: In detail, treating diabetic mice with SGLT2i attenuated hyperglycaemia, dyslipidaemia, renal lipotoxicity, glomerular damage, and albuminuria, as well as increased renal PPARα and PPARγ with concurrent decreases in several inflammatory and oxidative stress markers [41,42,43,44].